PATENT CLAIM ANALYSIS

Application Number: 16210492
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "279000"]

Abstract:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Claim (Index 1):
A compound represented by Formula (IIIa-7), (IIIb-7), (IIIc-7), or (IIId-7), or a pharmaceutically acceptable salt thereof, wherein:\n A 1  is a optionally substituted 5-membered heteroaryl group containing 1 to 4 heteroatoms selected from O, N, and S; \n A 2  is an optionally substituted phenyl, thiophenyl or 6-membered heteroaryl group; \n X 1  is optionally substituted methyl, halo, CN, OR 11 , or NR 11 R 12 ; \n m is 0, 1, 2, 3, 4 or 5; \n R 5  is selected from the group consisting of hydrogen, optionally substituted \u2014C 1 -C 8  alkyl, optionally substituted \u2014C 2 -C 8  alkenyl, optionally substituted \u2014C 2 -C 8  alkynyl, optionally substituted \u2014C 3 -C 8  cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, \u2014C(O)R 11 , \u2014C(O)OR 11 , \u2014C(O)NR 11 R 12 , \u2014S(O) 2 R 11 , \u2014S(O) 2 NR 11 R 12 , and \u2014C(O)NR 12 S(O) 2 R 12 ; and \n R 11 , R 12  and R 20  at each occurrence are independently selected from the group consisting of hydrogen, optionally substituted \u2014C 1 -C 8  alkyl, optionally substituted \u2014C 2 -C 8  alkenyl, optionally substituted \u2014C 2 -C 8  alkynyl, optionally substituted \u2014C 3 -C 8  cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.72131
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16210472', '15209150', '15421777', '15216124', '15088517']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8294567458856302
- 35 USC 102 Novelty (BERT): 0.572496421312585
- Combined Prediction Score: 0.8037607134283257
- Mean Citation Score: 404.732338
- Max Citation Score: 427.52896
- Similarity Product: 368.908427862854

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test